AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.30
-0.06 (-4.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.36
Open1.36
Bid1.20 x 800
Ask1.38 x 800
Day's Range1.30 - 1.36
52 Week Range0.79 - 3.85
Volume139,125
Avg. Volume259,009
Market Cap21.711M
Beta2.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research3 months ago

    AEMD: Q3 Results. Hemopurifier Pathway Could Benefit From New FDA Mindset

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...

  • Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?
    Simply Wall St.4 months ago

    Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?

    Aethlon Medical Inc (NASDAQ:AEMD), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered, smallRead More...

  • Benzinga4 months ago

    Aethlon Shares Jump Before '60 Minutes' Report On CTE, Vets

    Aethlon Medical (NASDAQ: AEMD ) reportedly plays a part in a “60 Minutes” segment on CTE in combat veterans that’s airing Sunday. The story says combat veterans exposed to bomb blasts are being diagnosed ...

  • How Does Aethlon Medical Inc’s (NASDAQ:AEMD) Earnings Growth Stack Up Against Industry Performance?
    Simply Wall St.5 months ago

    How Does Aethlon Medical Inc’s (NASDAQ:AEMD) Earnings Growth Stack Up Against Industry Performance?

    When Aethlon Medical Inc (NASDAQ:AEMD) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • What Investors Should Know About Aethlon Medical Inc’s (AEMD) Financial Strength
    Simply Wall St.6 months ago

    What Investors Should Know About Aethlon Medical Inc’s (AEMD) Financial Strength

    While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of USD $14.62M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • Zacks Small Cap Research6 months ago

    AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway

    Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018.  Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike).  AEMD expects current cash (i.e.

  • How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?
    Simply Wall St.7 months ago

    How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?

    Aethlon Medical Inc (NASDAQ:AEMD), a USD$14.64M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • Should You Have Aethlon Medical Inc’s (AEMD) In Your Portfolio?
    Simply Wall St.8 months ago

    Should You Have Aethlon Medical Inc’s (AEMD) In Your Portfolio?

    If you are looking to invest in Aethlon Medical Inc’s (NASDAQ:AEMD), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Zacks Small Cap Research9 months ago

    AEMD: EAP Filed, Expect FDA Response By Mid-September

    The major highlight on the operational front since our last update (on June 30th) was submission of the anticipated application to FDA seeking EAP designation for the Hemopurifier.  In an 8-K, filed earlier this week, Aethlon disclosed that they received formal receipt from the FDA of their EAP submission.  Per FDA guidance, the agency’s goal is to make a decision within 30 days (~mid-September) whether to grant EAP designation, or in the event additional information is required, to formally request that the sponsor (i.e.

  • Forbes9 months ago

    Former NFL Pro Supports Study Of Brain Injuries And Dementia In Football

    James Joyce, who played football for the Denver Broncos, is now supporting biotech research aimed at answering questions about the link between repeated head blows and dementia.

  • Capital Cube10 months ago

    ETFs with exposure to Aethlon Medical, Inc. : August 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Research11 months ago

    AEMD: Feasibility Study Validates Capture, EAP FDA Filing Is Next

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q4 2017 Financials, Operational Update… Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal fourth quarter 2017 ending March 31st and provided ...